MedWatch

Bank sees increasing likelihood of third Novo Nordisk upgrade

In a new memo, Citi bank concludes that there is a good chance that Novo Nordisk will upgrade its financial guidance again in November, based on sales of obesity drug Wegovy.

Photo: Novo Nordisk / PR

US-based bank Citi assesses that it is increasingly likely that Novo Nordisk will upgrade its financial guidance for the third time this year in connection with its Q3 report, which will be released at the start of November.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs